Detalles de la búsqueda
1.
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Lancet
; 402(10399): 373-385, 2023 07 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37311468
2.
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
Br J Haematol
; 198(2): 317-327, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35476316
3.
Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.
Br J Haematol
; 195(2): 244-248, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34331348
4.
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
Am J Hematol
; 95(6): 594-603, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32129512
5.
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis.
Blood Adv
; 2024 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38820422
6.
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes.
Blood Adv
; 6(7): 2207-2218, 2022 04 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34972214
7.
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML.
Blood Adv
; 6(7): 2219-2229, 2022 04 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34933333
8.
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial.
Hemasphere
; 5(5): e553, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33969273
9.
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial.
Hemasphere
; 5(5): e562, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33969275
10.
Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies.
Clin Pharmacokinet
; 59(2): 217-227, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31332669
11.
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer.
Clin Cancer Res
; 26(18): 4767-4776, 2020 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32611648
12.
Deep venous thrombosis caused by inferior vena cava atresia and hereditary thrombophilia.
Am J Med Sci
; 337(1): 67-70, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19002010
13.
Cyanotic congenital heart disease (CCHD) with symptomatic erythrocytosis.
J Gen Intern Med
; 22(12): 1775-7, 2007 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17917783
14.
The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis.
Clin Lymphoma Myeloma Leuk
; 22(7): e463-e466, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35120852
15.
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.
J Clin Oncol
; 35(12): 1304-1311, 2017 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-28240971
16.
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
J Clin Oncol
; 34(31): 3733-3739, 2016 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27354476
17.
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).
Leuk Res
; 48: 92-100, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27544076
18.
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
J Clin Oncol
; 34(36): 4354-4361, 2016 12 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-27998224
19.
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.
J Clin Oncol
; 34(36): 4371-4380, 2016 12 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-27601554
20.
Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody.
Eur J Cancer
; 66: 91-4, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27544928